Who
Carole Huntsman
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Madrigal Pharmaceuticals.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $3.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Nov 2023
- Last trade
- 6 Mar 2026
- Last filed
- 6 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $181K419 at $431.94 | filing |
| 6 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $181K419 at $431.94 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —3,989 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —4,986 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MDGL Madrigal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —4,986 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —3,989 at $0.00 | filing |
| 26 Jan 2026filed 26 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $167K340 at $492.42 | filing |
| 26 Jan 2026filed 26 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $282K570 at $494.59 | filing |
| 26 Jan 2026filed 26 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $167K340 at $492.42 | filing |
| 26 Jan 2026filed 26 Jan 2026 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $282K570 at $494.59 | filing |
| 21 Nov 2025filed 21 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $493K894 at $550.97 | filing |
| 21 Nov 2025filed 21 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $79K144 at $547.27 | filing |
| 21 Nov 2025filed 21 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $66K120 at $548.71 | filing |
| 21 Nov 2025filed 21 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $22K40 at $549.34 | filing |
| 21 Nov 2025filed 21 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $110K200 at $552.38 | filing |
| 21 Nov 2025filed 21 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $22K40 at $553.23 | filing |
| 21 Nov 2025filed 21 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $67K120 at $556.04 | filing |
| 21 Nov 2025filed 21 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $112K200 at $559.60 | filing |
| 21 Nov 2025filed 21 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $45K80 at $560.62 | filing |
| 21 Nov 2025filed 21 Nov 2025 | MDGL Madrigal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $23K40 at $563.21 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)MDGL · themarketsdaily.com · 20 Oct 2026Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)MDGL · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Carole Huntsman; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.